Provectus shareholders approve reverse stock split authorization and other proposals at annual meeting

PROVECTUS BIOPHARMACEUTICALS, INC.

All six proposals passed at June 20, 2024 annual meeting; directors elected with >96% votes cast.
Reverse stock split (1:10 to 1:50) authorized with 302.9M for (92.4%); authorized share reduction also approved.
Advisory vote on executive compensation passed with 202.8M for (96.6%); broker non-votes 115.0M.
Marcum LLP ratified as auditor for 2024 with 325.7M for (99.6%); no broker non-votes.
2024 Equity Compensation Plan approved with 198.3M for (94.0%); broker non-votes 115.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.